Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3000 participants.
Also called NCT02869009
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,000 participants
- Registry
-
NCT02869009
-
- Other papers using this trial's data
- Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke: The ATAMIS Randomized Clinical Trial
- Dual Antiplatelet Therapy and Outcomes in Acute Mild to Moderate Stroke With Versus Without Large-Artery Atherosclerosis Post Hoc Analysis of ATAMIS
- Early Neurologic Deterioration and Efficacy of Dual Antiplatelet in Anterior Versus Posterior Circulation Stroke
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02869009. Randomized; no masking; primary purpose treatment. Start 2016-11 (actual); primary completion 2022-10-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke
- Acronym
- ATAMIS
- Condition
- Ischemic Stroke
- Intervention (Drug)
- clopidogrel
- Intervention (Drug)
- Aspirin
- Lead sponsor
- General Hospital of Shenyang Military Region
Record details
- Record id
cardio:ct-nct02869009- Content hash
57ebcfcda502ea13f0643d31a4b8062af1b7032cb47589b15120ebd83e9556e6